Journal: Archives of Medical Science : AMS

Article Title: Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma

doi: 10.5114/aoms.2017.65272

Figure Lengend Snippet: Detection of β-catenin, E- and N-cadherins and the cellular localization of the proteins in chronic hepatitis C (CH-C), hepatocellular carcinoma (HCC) and normal liver (control)

Article Snippet: Mouse anti-human monoclonal antibodies (mAbs) were employed, directed against human beta-catenin (Clone 196618; Code M 7052) (in dilution 1 : 50) (R&D Systems, UK), against E-cadherin (clone NCH-38) (in dilution 1 : 100) (DakoCytomation, Gdynia, PL) and against N-cadherin (in dilution 1 : 50) (clone IAR06) (Novocastra Labs. Ltd, Newcastle upon Tyne, UK).

Techniques: Control

Journal: Archives of Medical Science : AMS

Article Title: Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma

doi: 10.5114/aoms.2017.65272

Figure Lengend Snippet: Immunohistochemical ( A – C ) and hybridocytochemical localization of β-catenin ( D ) in liver. Membranous/ cytoplasmic localization of β-catenin in liver with chronic hepatitis C ( A ), membranous localization of β-catenin in hepatocellular carcinoma ( B ) and in control liver ( C ); mRNA for β-catenin in cytoplasm and cell nuclei in HCC fragment ( D ). Immunocytochemical detection of E-cadherin ( E – F ) and N-cadherin ( H ) in liver. Predominantly membranous localization of E-cadherin in liver with chronic hepatitis C ( E ), hepatocellular carcinoma ( F ) and control liver ( G ). Membrano-cytoplasmic localization of N-cadherin in fragment of hepatocellular carcinoma ( H ). Immunohistochemistry ( A – C , E – H ) technique and hybridization in situ method ( D ). Hematoxylin counterstained. Bar = 40 μm

Article Snippet: Mouse anti-human monoclonal antibodies (mAbs) were employed, directed against human beta-catenin (Clone 196618; Code M 7052) (in dilution 1 : 50) (R&D Systems, UK), against E-cadherin (clone NCH-38) (in dilution 1 : 100) (DakoCytomation, Gdynia, PL) and against N-cadherin (in dilution 1 : 50) (clone IAR06) (Novocastra Labs. Ltd, Newcastle upon Tyne, UK).

Techniques: Immunohistochemical staining, Control, Immunohistochemistry, Hybridization, In Situ

Journal: Archives of Medical Science : AMS

Article Title: Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma

doi: 10.5114/aoms.2017.65272

Figure Lengend Snippet: Comparison of quantitatively assessed β-catenin, E-cadherin and N-cadherin immunoexpression (% of the IHC reaction area in analysed area of liver parenchyma) in chronic hepatitis C (CH-C), hepatocellular carcinoma (HCC) and normal liver (C)

Article Snippet: Mouse anti-human monoclonal antibodies (mAbs) were employed, directed against human beta-catenin (Clone 196618; Code M 7052) (in dilution 1 : 50) (R&D Systems, UK), against E-cadherin (clone NCH-38) (in dilution 1 : 100) (DakoCytomation, Gdynia, PL) and against N-cadherin (in dilution 1 : 50) (clone IAR06) (Novocastra Labs. Ltd, Newcastle upon Tyne, UK).

Techniques: Comparison

Journal: Archives of Medical Science : AMS

Article Title: Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma

doi: 10.5114/aoms.2017.65272

Figure Lengend Snippet: Comparative immunoexpression of β-catenin, E-cadherin and N-cadherin in liver with chronic hepatitis C (CH-C), hepatocellular carcinoma (HCC) and normal organ (control) ***p (level of significance) value < 0.001, *p < 0.05.

Article Snippet: Mouse anti-human monoclonal antibodies (mAbs) were employed, directed against human beta-catenin (Clone 196618; Code M 7052) (in dilution 1 : 50) (R&D Systems, UK), against E-cadherin (clone NCH-38) (in dilution 1 : 100) (DakoCytomation, Gdynia, PL) and against N-cadherin (in dilution 1 : 50) (clone IAR06) (Novocastra Labs. Ltd, Newcastle upon Tyne, UK).

Techniques: Control

Journal: Archives of Medical Science : AMS

Article Title: Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma

doi: 10.5114/aoms.2017.65272

Figure Lengend Snippet: Tissue expression of β-catenin, E-cadherin and N-cadherin (mean % of IHC reaction area ± SD) as related to grading and staging in chronic hepatitis C (CH-C) group

Article Snippet: Mouse anti-human monoclonal antibodies (mAbs) were employed, directed against human beta-catenin (Clone 196618; Code M 7052) (in dilution 1 : 50) (R&D Systems, UK), against E-cadherin (clone NCH-38) (in dilution 1 : 100) (DakoCytomation, Gdynia, PL) and against N-cadherin (in dilution 1 : 50) (clone IAR06) (Novocastra Labs. Ltd, Newcastle upon Tyne, UK).

Techniques: Expressing

Journal: Archives of Medical Science : AMS

Article Title: Tissue expression of β-catenin and E- and N-cadherins in chronic hepatitis C and hepatocellular carcinoma

doi: 10.5114/aoms.2017.65272

Figure Lengend Snippet: Values of Spearman’s rank coefficient between expression of β-catenin, E-cadherin, N-cadherin (% IHC reaction area per area of hepatic parenchyma) and clinicopathological data in CH-C group

Article Snippet: Mouse anti-human monoclonal antibodies (mAbs) were employed, directed against human beta-catenin (Clone 196618; Code M 7052) (in dilution 1 : 50) (R&D Systems, UK), against E-cadherin (clone NCH-38) (in dilution 1 : 100) (DakoCytomation, Gdynia, PL) and against N-cadherin (in dilution 1 : 50) (clone IAR06) (Novocastra Labs. Ltd, Newcastle upon Tyne, UK).

Techniques: Expressing, Infection

Journal: Respiratory Research

Article Title: ROBO2 signaling in lung development regulates SOX2/SOX9 balance, branching morphogenesis and is dysregulated in nitrofen-induced congenital diaphragmatic hernia

doi: 10.1186/s12931-020-01568-w

Figure Lengend Snippet: Effect of ROBO1 or ROBO2 functional impairment in branching morphogenesis. a The upper panel is representative of untreated lung explants (0 ng/mL) at D0; the bottom panel represents lung explants treated with recombinant IgG protein (0 ng/mL) and several doses of recombinant ROBO1 or ROBO2 proteins at day 4 (D4). b Morphometric analysis of the number of peripheral airway buds of fetal rat lung explants treated with increasing concentrations of recombinant ROBO1 (black) and ROBO2 (gray) proteins. Results are expressed as the D4/D0 ratio. c Examples of representative blots are showed for each analysed protein. Protein expression levels of d ROBO; e SOX2; f SOX9; g total β-Catenin; h non-phospho (active) β-Catenin; and i BMP4 in normal explant cultures treated with recombinant rat ROBO1 Fc Chimera for ROBO1 inhibition (black line) or recombinant human ROBO2 Fc Chimera for ROBO2 functional impairment (gray line). Recombinant human IgG Fc was used as control (IgG). n ≥ 9 per protein/condition. Each lane represents a pooled-tissue sample, and relative expression was determined against β-Tubulin and IgG. The data are presented as means ± SEM. p < 0.05: α vs. IgG

Article Snippet: Blots were blocked in 5% bovine serum albumin and probed with primary antibodies to ROBO1 (1:500, ON, 4 oC; Cat No. sc25672, Santa Cruz Biotechnology Inc., USA), ROBO2 (1:250, ON, 4 oC; Cat No. sc16615, Santa Cruz Biotechnology Inc. USA), SOX2 (1:250, ON, 4 oC; Cat No. AF2018, R&D system, USA), SOX9 (1:250, ON, 4 oC; Cat No. AF3075, R&D system, USA), non-phospho (Active) β-Catenin (Ser33/37/Thr41) (1∶5000; Cat No. #4270, Cell Signaling Technology Inc., USA), total β-Catenin (1∶30,000; Cat No. #NBP1-54,467, NOVUS Biologicals, USA), and BMP4 (1:250, ON, 4 oC; Cat No. sc-6896, Santa Cruz Biotechnology Inc., USA) according to the manufacturer's instructions.

Techniques: Functional Assay, Recombinant, Expressing, Inhibition, Control

Journal: Respiratory Research

Article Title: ROBO2 signaling in lung development regulates SOX2/SOX9 balance, branching morphogenesis and is dysregulated in nitrofen-induced congenital diaphragmatic hernia

doi: 10.1186/s12931-020-01568-w

Figure Lengend Snippet: a Overview of the main changes in spatiotemporal distribution of ROBO1, ROBO2, SOX2 and SOX9 at pseudoglandular (E17.5) and saccular stages (E21.5) in hypoplastic (hyp) fetal lungs (lower panel). w/o without b A proposed model of ROBO regulation of ex vivo branching morphogenesis through BMP4, β-Catenin, SOX2 and SOX9

Article Snippet: Blots were blocked in 5% bovine serum albumin and probed with primary antibodies to ROBO1 (1:500, ON, 4 oC; Cat No. sc25672, Santa Cruz Biotechnology Inc., USA), ROBO2 (1:250, ON, 4 oC; Cat No. sc16615, Santa Cruz Biotechnology Inc. USA), SOX2 (1:250, ON, 4 oC; Cat No. AF2018, R&D system, USA), SOX9 (1:250, ON, 4 oC; Cat No. AF3075, R&D system, USA), non-phospho (Active) β-Catenin (Ser33/37/Thr41) (1∶5000; Cat No. #4270, Cell Signaling Technology Inc., USA), total β-Catenin (1∶30,000; Cat No. #NBP1-54,467, NOVUS Biologicals, USA), and BMP4 (1:250, ON, 4 oC; Cat No. sc-6896, Santa Cruz Biotechnology Inc., USA) according to the manufacturer's instructions.

Techniques: Ex Vivo

Journal: Nutrients

Article Title: Limonin, a Component of Immature Citrus Fruits, Activates Anagen Signaling in Dermal Papilla Cells

doi: 10.3390/nu14245358

Figure Lengend Snippet: Limonin induces cell proliferation via activation of the Wnt/β-catenin pathway in two-dimensional (2D) cultured rDPC. ( A ) Representative images of Western blot for Wnt/β-catenin-related proteins phospho(Ser552)-β-catenin and phospho(Ser675)-β-catenin after treatment with limonin and minoxidil for 24 h. ( B ) Confocal microscopy images for changes in the cellular localization of phospho(Ser675)-β-catenin after treatment with limonin and minoxidil for 1 h. ( C ) Confocal microscopy images of changes in the number of LC3B puncta after treatment with limonin for 24 h in the absence or presence of XAV939. ( D ) Changes in the proliferation of 2D rDPC after treatment with limonin for 3 days with or without XAV939. ( E ) Confocal microscopy images for changes in the number of BrdU-positive cells after treatment with limonin for 24 h in the absence or presence of XAV939. * p < 0.05 vs. vehicle-treated control. †† p < 0.01 vs. limonin alone. Scale bars, 50 μm. Con, vehicle-treated control; NT, not treated; NS, not significant.

Article Snippet: Phospho(Ser675)-β-catenin , Rabbit , 1:1000 , Cell Signaling.

Techniques: Activation Assay, Cell Culture, Western Blot, Confocal Microscopy, Control